3D QSAR study of hypolipidemic asarones by comparative molecular surface analysis

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 5, 2006, Pages 1630-1643

  Magdziarz, Tomasz ^a   Łozowicka, Bozena ^b   Gieleciak, Rafał ^a   Ba̧k, Andrzej ^a   Polański, Jarosław ^a   Chilmonczyk, Zdzisław ^b,c  

^a UNIVERSITY OF SILESIA   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Asarone analogues; Hypolipidemic activity; QSAR study

Indexed keywords

3 (4 METHYLPIPERIDIN 1 YL) 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 ONE; 3 AZEPAN 1 YL 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 ONE; 3 MORPHOLIN 4 YL 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 OL; 3 MORPHOLIN 4 YL 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 ONE; 3 PIPERIDIN 1 YL 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 OL; 3 PIPERIDIN 1 YL 1 (3,4,5 TRIMETHOXYPHENYL)PROPAN 1 ONE; 4 [3 (3,4,5 TRIMETHOXYPHENYL)PROP 2 ENYL]MORPHOLINE; ANTILIPEMIC AGENT; ASARONE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRICITY; HYPOLIPEMIA; MALE; NONHUMAN; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SURFACE PROPERTY; THREE DIMENSIONAL IMAGING;

ANISOLES; ANTILIPEMIC AGENTS; COMPUTER SIMULATION; DRUG DESIGN; ELECTROSTATICS; FIBRINOLYTIC AGENTS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 31044431624     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.10.014     Document Type: Article

References (46)

1. K.M. Anderson, P.W.F. Wilson, P.M. Odell, and W.B. Kannel Circulation 83 1991 356
2. L.F. Van Gaal, A. Hang, Mm. Steijaert, and Ih. De Leeuw Int. J. Obes. 19 1995 S21
3. K.S. McCully Nat. Med. 2 1996 386
4. Bg. Brown, X. Zhao, De. Sacco, and J.J. Albers Circulation 87 1993 1781
5. J.J. Badimon, V. Fuster, and L. Badimon Circulation 86 1992 II-86 III-94
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001, 285, 2486.
7. Z. Chilmonczyk, D. Siluk, and R. Kaliszan Exp. Opin. Ther. Pat. 11 2001 1301
8. G. Levine, J. Keaney, and J. Vita N. Engl. J. Med. 332 1995 512
9. P.O. Szapary, and D.J. Rader Am. Heart. J. 148 2004 211
10. B. Eghdamian, and K. Ghose Drugs Today 35 1988 79
11. J.A. Farmer, and A. Gotto Jr. Adv. Pharmacol. 35 1966 79
12. R. Enriquez, M. Chávez, and F. Jáuregui Phytochemistry 19 1980 2024
13. G. Chamorro, L. Garduno, A. Sanchez, F. Labarrios, M. Salazar, E. Martinez, F. Diaz, and J. Tamariz Drug Dev. Res. 43 1998 105
14. F. Labarrios, L. Garduno, M. Vidal, R. Garcia, M. Salazar, E. Martinez, F. Diaz, G. Chamorro, and J. Tamariz J. Pharm. Pharmacol. 51 1999 1
15. P.C. Dandiya, and J.D. Sharma Ind. J. Med. Res. 50 1962 46
16. P.C. Dandiya, and M.K. Menon Br. J. Pharmacol. 20 1963 436
17. L. Belova, S. Alibekov, A. Baginskaya, S. Sokolov, G. Pokrovskaya, V. Stikhin, T. Trumpe, and T. Gorodnyuk Farmak. Toksikol. 48 1985 17
18. R. Morales, B. Madrigal, M. Mercader, M. Cassani, G. Gonzalez, G. Chamorro, and M. Salazar Mutat. Res. 279 1992 269
19. M. Salazar, S. Salazar, V. Ulloa, T. Mendoza, N. Pages, and G. Chamorro J. Toxicol. Clin. Exp. 12 1992 149
20. F. Diaz, L. Contreras, R. Flores, J. Tamariz, F. Labarrios, G. Chamorro, and H. Munoz Org. Prep. Proc. Int. 24 1992 78
21. S. Filipek, and B. Łozowicka Acta Pol. Pharm. 57 2000 106
22. M. Cruz, M. Salazar, Y. Garciafigueroa, D. Hernandez, F. Diaz, G. Chamorro, and J. Tamariz Drug Dev. Res. 60 2003 186
23. A. Cruz, L. Garduno, M. Salazar, E. Martinez, H. Jimenez-Vazquez, F. Diaz, G. Chamorro, and J. Tamariz Arzneim.-Forsch./Drug Res. 51 2001 535
24. J. Poplawski, B. Lozowicka, A. Dubis, B. Lachowska, S. Witkowski, D. Siluk, J. Petrusewicz, R. Kaliszan, J. Cybulski, Z. Chilmonczyk, and M. Strzalkowska J. Med. Chem. 43 2000 3671
25. Lozowicka, B.; Filipek, S.; Dubis, A. Eur. J. Med. Chem. (submitted).
26. Lozowicka, B.; Poplawski, J.; Dubis, A.; Chilmonczyk, Z.; Cybulski, J.; Kita, K.; Kobes, S.; Filipek, S. Drug Dev. Res. (submitted).
27. Z. Chilmonczyk, D. Siluk, R. Kaliszan, B. Lozowicka, J. Poplawski, and S. Filipek Pure Appl. Chem. 73 2001 1445
28. J. Polanski, and B. Walczak Comp. Chem. 24 2000 615
29. J. Polanski, R. Gieleciak, and A. Bak J. Chem. Inf. Comput. Sci. 42 2002 184
30. J. Polanski, and R. Gieleciak J. Chem. Inf. Comput. Sci. 43 2003 656
31. J. Polanski, R. Gieleciak, and M. Wyszomirski J. Chem. Inf. Comput. Sci. 43 2003 1754
32. J. Polanski, R. Gieleciak, and M. Wyszomirski Dyes Pigments 62 2004 63
33. J. Polanski, and R. Gieleciak Mol. Diversity 7 2003 45
34. J. Polanski, R. Gieleciak, and A. Bak Comb. Chem. High Throughput Screen. 7 2004 793
35. J. Polanski, A. Bak, R. Gieleciak, and T. Magdziarz Molecules 9 2004 1148
36. J. Polanski, R. Gieleciak, T. Magdziarz, and A. Bak J. Chem. Inf. Comput. Sci. 44 2004 1423
37. MATLAB 5.0 program. Available from: The Mathworks Inc., Natick, MA, USA, http://www.mathworks.com.
38. V. Centner, D.L. Massart, O.E. de Noord, S. de Jong, B.M.V. Vandeginste, and C. Sterna Anal. Chim. Acta 330 1996 1
39. J. Polanski, and A.J. Bak Chem. Inf. Comput. Sci. 43 2003 208
40. F. Blicke, and J. Bruckhalter J. Am. Chem. Soc. 64 1942 451
41. B. Testa, and W.P. Purcell Eur. J. Med. Chem. 13 1978 509
42. I. Motoc Molecular Shape Descriptors M. Charton I. Motoc Steric Effects in Drug Design 1983 Akademie Berlin 93 105
43. K. Hasegawa, S. Matsuoka, M. Arakawa, and K. Funatsu Comput. Chem. 26 2002 583
44. K. Hasegawa, K. Morikami, Y. Shiratori, T. Ohtsuka, Y. Aoki, and N. Shimma Chemometr. Intell. Lab. Syst. 69 2003 51
45. K. Hasegawa, S. Matsuoka, M. Arakawa, and K. Funatsu Comput. Biol. Chem. 27 2003 381
46. R.W. Kennard, and L.A. Stone Technometrics 11 1969 137